A Phase 1, Double Blind, Randomized, Placebo Controlled, Single Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZD03 Capsule in Healthy Volunteers in The United States
Latest Information Update: 02 Nov 2021
At a glance
- Drugs ZD 03 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Shanxi Zhendong Leading Biotechnology
- 08 Jan 2021 New trial record